CCR1 and metastatic melanoma: Recently, other new CCR1 antagonists have been reported in preclinical studies; for example, J-113863 showed efficacy in animal models of metastatic melanoma, multiple sclerosis and autoimmune encephalomyelitis, while BX471 was tested in models of asthma [37, 42–44].